ACR Convergence 2023

November 10-15, 2023. San Diego, CA.

View by Number View by Title View Sessions

Sunday, November 12, 2023

9:00AM-11:00AM: Abstract Number: 0353

Validation of Claims-based Algorithms for Newly Diagnosed Juvenile Idiopathic Arthritis Using Machine Learning Methods

(0345–0379) Pediatric Rheumatology – Clinical Poster I: JIA

9:00AM-11:00AM: Abstract Number: 0322

Validation of NICE Criteria for the Diagnosis of Knee Osteoarthritis

(0308–0324) Osteoarthritis – Clinical Poster I

9:00AM-11:00AM: Abstract Number: 0250

Validation of Singe-Shot Computational Polarized Microscopy for Crystal Analysis of Synovial Fluid

(0229–0251) Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I

9:00AM-11:00AM: Abstract Number: 0357

Validation of the Juvenile Spondyloarthritis Disease Activity Index in a Prospective Clinical Trial Setting

(0345–0379) Pediatric Rheumatology – Clinical Poster I: JIA

9:00AM-11:00AM: Abstract Number: 0267

Variations in Approach to the Diagnosis and Management of Polymyalgia Rheumatica Among Australian Rheumatologists

(0252–0282) Miscellaneous Rheumatic & Inflammatory Diseases Poster I

9:00AM-11:00AM: Abstract Number: 0229

Vegetable Consumption and Regular Exercise Are Associated with Better Quality of Life in Gout

(0229–0251) Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I

9:00AM-11:00AM: Abstract Number: 0242

Venous Thromboembolism in Patients with Gout in the US

(0229–0251) Metabolic & Crystal Arthropathies – Basic & Clinical Science Poster I

9:00AM-11:00AM: Abstract Number: PP11

We Suffered For Decades, But Then She Was Born

Patient Perspectives Poster

9:00AM-11:00AM: Abstract Number: 0168

What Are the Characteristics of a Cost-Effective Psoriatic Arthritis Biomarker Test? An Early Health Technology Assessment

(0155–0175) Health Services Research Poster I

9:00AM-11:00AM: Abstract Number: 0213

When Should I Get My Next Booster? Active Surveillance of COVID-19 Breakthrough Infections in Canadian Patients with Immune-Mediated Inflammatory Diseases

(0196–0228) Infection-related Rheumatic Disease Poster

9:00AM-11:00AM: Abstract Number: 0517

Which ASDAS Cut-Off Corresponds Best to Treatment Intensification in Patients with Axial Spondyloarthritis in Daily Practice?

(0510–0542) Spondyloarthritis Including Psoriatic Arthritis – Treatment: AxSpA Poster I

9:00AM-11:00AM: Abstract Number: 0521

Work Productivity Improved in Patients with Axial Spondyloarthritis Receiving Bimekizumab Treatment over 52 Weeks: Results from Two Phase 3 Studies

(0510–0542) Spondyloarthritis Including Psoriatic Arthritis – Treatment: AxSpA Poster I

9:00AM-11:00AM: Abstract Number: 0017

Xist Ribonucleoproteins Promote Female Sex-biased Autoimmunity

(0013–0039.5) Genetics, Genomics & Proteomics Poster

9:00AM-11:00AM: Abstract Number: PP01

You Can’t Get This from a Doctor: The Role of Support Groups for Adults Aged 25-55 Living with Arthritis

Patient Perspectives Poster

11:00AM-12:30PM: Abstract Number: 0722

Acute Cardiovascular Events in Autoimmune Rheumatic Disease Pregnancies

Plenary I

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].